The goal of this observational study is to learn about the long-term effects of Lorlatinib related hyperlipidemia in NSCLC patients who take Lorlatinib for at least 21 days. The main question it aims to answer is: * Whether blood lipids have been lowered down to an anticipated level within recommended range after the initial revealed Lorlatinib related hyperlipidemia? * Will it be harmful to the cardiovascular system when blood lipids were not lowered down to normal levels in these cancer patients treated with Lorlatinib, i.e. major adverse cardiac events (MACE), or instead, carotid artery intima-media thickness. Participants already taking Lorlatinib as part of their regular medical care for NSCLC will answer online survey questions.
Study Type
OBSERVATIONAL
Enrollment
167
To study hyperlipidemia frequency, levels, impact on cardiovascular events after use of Lorlatinib in NSCLC patients.
Peking University Third Hospital
Beijing, China
Alteration from baseline to 2 years after first dose of Lorlatinib: maximum carotid intima-media thickness and coronary CT calcification score.
Maximum carotid intima-media thickness: the higher the worse. It is a value directly determined under carotid ultrasound. CT: Computed Tomography Coronary CT calcification score: the higher the worse. It is a value directly determined by coronary calcium scan.
Time frame: From first dose of Lorlatinib to 2 years thereafter.
Numbers and Time of Major adverse cardiovascular events in patients with Lorlatinib-related hyperlipidemia.
Time frame: From first dose of Lorlatinib to at maximum of 10 years thereafter.
Comparison of predictive effect on MACE between change in maximum carotid intima-media thickness and coronary artery calcium score.
Time frame: From first dose of Lorlatinib to at maximum of 10 years thereafter.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.